NCT07068542View on ClinicalTrials.gov

Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer

NANot yet recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Advanced Thyroid CarcinomaRadioiodine-refractory Differentiated Thyroid Cancer
Interventions
DRUG

Sacituzumab tirumotecan

Sacituzumab tirumotecan: 4mg/kg, IV, Q6W, D1, D15, D22

DRUG

Tislelizumab

Tislelizumab: 400mg, IV, Q6W, D1

All Listed Sponsors
lead

Zhejiang Provincial People's Hospital

OTHER